Study Stopped
Sponsor decision, not safety related.
A Study of Complex Ventral Hernia Repair Utilizing the XenMatrix™ Surgical Graft With Component Separation
XenMatrix
A Prospective, Multi-Center Study of Complex Ventral Hernia Repair Utilizing the XenMatrix™ Surgical Graft With Component Separation
1 other identifier
observational
4
1 country
1
Brief Summary
This will be an observational study designed to collect early, short- and long-term clinical outcomes of the XenMatrix™ Surgical Graft for complex ventral hernia repair. Subjects will be expected to attend follow up visits at 1, 6, 12, 18 and 24 months following surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2010
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2010
CompletedFirst Submitted
Initial submission to the registry
December 22, 2010
CompletedFirst Posted
Study publicly available on registry
February 28, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2011
CompletedJanuary 15, 2013
January 1, 2013
9 months
December 22, 2010
January 14, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
To estimate the hernia recurrence rate of complex ventral hernias post repair with the XenMatrix™ Surgical Graft utilizing the component separation technique with several different tissue plane placements of the graft for up to 24 months post surgery.
Any hernia which is identified or confirmed by the investigator in approximately the same position as the hernia repair during any follow up visit after a XenMatrix™ surgical graft has been placed will be considered a recurrent hernia.
2 Years
Secondary Outcomes (4)
To assess perioperative, short-term and long-term complications in subjects with complex hernias repaired with XenMatrix™ Surgical Graft and component separation.
2 Years
To assess the procedural time for XenMatrix™ Surgical Graft placement with component separation.
Day 0
To assess changes in subject quality of life (QOL) post repair with a XenMatrix™ Surgical Graft with component separation.
2 years
To assess clinical outcomes based on the tissue plane placement of the XenMatrix™ Surgical Graft.
2 years
Study Arms (1)
XenMatrix
Eligibility Criteria
Subjects who are diagnosed with a ventral or incisional hernia that require a component separation repair with the use of a biological graft.
You may qualify if:
- Be able to undergo study procedures.
- Have signed an Informed Consent form (ICF).
- Be diagnosed with a ventral or incisional hernia that cannot be closed primarily in the opinion of the investigator.
- Requires a component separation repair with the use of a biological graft.
You may not qualify if:
- Subject is participating in another device or drug study.
- Subject has a life expectancy less than 4 years at the time of enrollment.
- Any condition in the opinion of the investigator that would preclude the use of the XenMatrix™ Surgical Graft, or preclude the subject from completing the follow-up requirements.
- Any subject with a defect the surgeon feels he/she cannot fully close.
- Subjects with a BMI \> 50.
- Subjects with connective tissue disorders.
- Subjects with a history of cirrhosis.
- Subjects with renal failure requiring dialysis.
- Subjects on or suspected to be placed on chemotherapy or systemic immunosuppressive medications during any part of the study.
- Transplant recipients.
- Subjects taking corticosteroids for \>6 months (pre or post surgery).
- Any bowel leak or infection that would preclude the use of the XenMatrix™ Surgical Graft in the opinion of the investigator.
- The subject lives approximately 2 hours away from the study site and compliance with follow up requirements will be difficult in the opinion of the investigator.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- C. R. Bardlead
Study Sites (1)
Our Lady of the Lake Regional Medical Center
Baton Rouge, Louisiana, 70808, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Karl LeBlanc, MD
Our Lady of the Lake Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 22, 2010
First Posted
February 28, 2011
Study Start
September 1, 2010
Primary Completion
June 1, 2011
Study Completion
June 1, 2011
Last Updated
January 15, 2013
Record last verified: 2013-01